Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study
- 1 January 2013
- journal article
- research article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 8 (9), 1006-1011
- https://doi.org/10.4244/eijv8i9a155
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 12 references indexed in Scilit:
- Coronary Stents: Looking ForwardJournal of the American College of Cardiology, 2010
- MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenosesEuropean Heart Journal, 2009
- Universal Definition of Myocardial InfarctionJournal of the American College of Cardiology, 2007
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary StentsThe New England Journal of Medicine, 2007
- Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic RiskJournal of the American College of Cardiology, 2006
- Coronary-Artery StentsThe New England Journal of Medicine, 2006
- Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantationEuropean Heart Journal, 2005
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryThe New England Journal of Medicine, 2003
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationThe New England Journal of Medicine, 2002